Tuesday Features

Alitair builds value without outside investors

Dr. William W. Howard likes to say there’s a lesson to be learned in how closely held Alitair Pharmaceuticals has spent the first couple years of its existence developing a portfolio of respiratory therapeutics and a drug safety technology: make some money first and then go out and get investors. Dr. William W. Howard “We’ve been able to develop... [Read more of this feature]

---

Novadaq partnering strategy hits marketing milestone

Novadaq Technologies (TSX:NDQ), a maker of real-time fluorescence imaging products for the operating room, reached a significant milestone earlier this month when it named MAQUET Cardiovascular as the exclusive distributor of its CO2 Heart Laser system in the U.S. Dr. Arun Menawat “We have now completed our strategic agenda of partnering each one... [Read more of this feature]

---

Cynapsus readies first human data of sublingual strip for PD

Cynapsus Therapeutics (TSX-V:CTH) is set to release human proof-of-concept data of its sublingual thin film-strip as a treatment for motor fluctuations, or episodes of immobility, in patients with Parkinson’s disease. Anthony Giovinazzo “This will represent an important de-risking event for the project,” CEO Anthony Giovinazzo says in an exclusive... [Read more of this feature]

---

More Posts From Tuesday Features

Briefs

Roth upgrades Spectrum to buy

Roth Capital Partners has upgraded Spectrum Pharmaceuticals (NASDAQ:SPPI) to “buy” from “neutral” and raised its 12-month price target to $20 from $11, citing an increasing focus on revenue and data catalysts in 2012. The stock was quoted at $13.93 Thursday afternoon. “We base our upgrade on our belief that Fusilev revenue... [Read more of this brief]

---

Navidea signs option to license PD imaging agent

Navidea Biopharmaceuticals (AMEX:NAVB), formerly Neoprobe,  has entered into a six-month option agreement with Alseres Pharmaceuticals to license [123I]-E-IAFCT Injection, also called Altropane, an Iodine-123 radio-labeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. “Should we... [Read more of this brief]

---

Roth starts Intellipharmaceutics at buy

Roth Capital Partners has initiated coverage of Intellipharmaceutics (NASDAQ:IPCI; TSX:I) with a “buy” rating and 12-month price target of $5.25, saying the emerging generics company could launch four new products in the coming 12-to-18 months. “We believe that this momentum could unlock value for this under covered stock,” writes... [Read more of this brief]

---

D. Medical inks fifth U.S. distributor of diabetic infusion sets

D. Medical Industries (NASDAQ, TASE:DMED) has signed a non-exclusive agreement with Solara Medical Supplies for the distribution of its Spring Universal Infusion Sets in the U.S. The accord has an initial term of two years, beginning with Solara’s initial order, and then automatically renewed for one-year periods. Spring Universal “We have... [Read more of this brief]

---

enGene establishes clinical advisory board

Closely held enGene has established a clinical advisory board of preeminent clinical investigators in the field of Inflammatory Bowel Disease (IBD) to provide the company with guidance on the regulatory pathway and clinical development of its EG-10 candidate for the treatment of ulcerative colitis. The newly appointed clinical advisors are Drs. Brian... [Read more of this brief]

---

More Posts From Briefs